BR0317294A - Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários - Google Patents
Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediáriosInfo
- Publication number
- BR0317294A BR0317294A BR0317294-5A BR0317294A BR0317294A BR 0317294 A BR0317294 A BR 0317294A BR 0317294 A BR0317294 A BR 0317294A BR 0317294 A BR0317294 A BR 0317294A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treatment
- prevention
- intermediates
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
"COMPOSTO, FORMULAçãO FARMACêUTICA, USO DE UM COMPOSTO, MéTODOS DE PREVENçãO E/OU TRATAMENTO DE CONDIçõES ASSOCIADAS COM A GLICOGêNIO SINTASE QUINASE-3 E DE PREVENçãO E/OU TRATAMENTO DE DOENçAS, E, USO DOS INTERMEDIáRIOS". A presente invenção diz respeito aos novos compostos da fórmula (I) em que: Z é N e X é CH ou N; Y é CONR¬ 5¬; pé fenila ou um anel heteroaromático de 5 ou 6 membros contendo um ou mais heteroátomos selecionados de N, O ou S; Q é fenila ou um anel heterocíclico aromático de 5 ou 6 membros contendo um ou mais átomos de nitrogênio; R é alquila C~ 1-6~NR¬ 10¬R¬ 11¬ ou alquilazetidina C~ 1-6~; R¬ 10¬ é hidrogênio, alquila C~ 1-6~, alquenila C~ 2-6~, alquinila C~ 2-6~, alquila C~ 0-6~cicloalquila C~ 3-6~, alquilarila C~ 0-6~, alquileteroarila C~ 0-61~ ou alquila C~ 1-6~NR¬ 8¬R¬ 9¬; R¬ 11¬ é alquila C~ 1-6~NR¬ 8¬R¬ 9¬, alquila C~ 0-6~cicloalquila C~ 3-6~ ou alquileterocicloalquila C~ 0-6~; como uma base livre ou um sal, solvato farmaceuticamente aceitáveis ou solvato do sal deste, um processo para sua preparação e novos intermediários usados nesta, formulações farmacêuticas contendo os ditos compostos terapeuticamente ativos e ao uso dos ditos compostos ativos em terapia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0203754A SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | New compounds |
PCT/SE2003/001955 WO2004055005A1 (en) | 2002-12-17 | 2003-12-15 | Novel compounds having selective inhibiting effect at gsk3 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0317294A true BR0317294A (pt) | 2005-11-08 |
Family
ID=20289907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0317294-5A BR0317294A (pt) | 2002-12-17 | 2003-12-15 | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários |
Country Status (19)
Country | Link |
---|---|
US (2) | US7585853B2 (pt) |
EP (2) | EP1575938B1 (pt) |
JP (1) | JP4674088B2 (pt) |
KR (1) | KR101110457B1 (pt) |
CN (1) | CN100351250C (pt) |
AT (1) | ATE454382T1 (pt) |
AU (1) | AU2003287135B2 (pt) |
BR (1) | BR0317294A (pt) |
CA (1) | CA2508042C (pt) |
DE (1) | DE60330910D1 (pt) |
ES (1) | ES2337682T3 (pt) |
HK (1) | HK1080856A1 (pt) |
IL (1) | IL169016A (pt) |
MX (1) | MXPA05006243A (pt) |
NO (1) | NO331495B1 (pt) |
NZ (1) | NZ540449A (pt) |
SE (1) | SE0203754D0 (pt) |
WO (1) | WO2004055005A1 (pt) |
ZA (1) | ZA200504617B (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
SE0203752D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
SE0203753D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
DK1784396T3 (da) * | 2004-08-26 | 2011-02-14 | Pfizer | Pyrazol-substituerede aminoheteroaryl-forbindelser som proteinkinase-inhibitorer |
BRPI0513915A (pt) * | 2004-08-26 | 2008-05-20 | Pfizer | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase |
EP2157090A4 (en) * | 2007-06-21 | 2011-09-07 | Taisho Pharmaceutical Co Ltd | PYRAZINAMIDVERBINDUNG |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
EP2138485A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
RU2011123647A (ru) | 2008-11-10 | 2012-12-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, полезные в качестве ингибиторов atr киназы |
PT3354650T (pt) | 2008-12-19 | 2022-06-20 | Vertex Pharma | Compostos úteis como inibidores da cinase atr |
US20110118275A1 (en) * | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | OXAZOLO[4,5-c]PYRIDINE SUBSTITUTED PYRAZINE |
KR20120120307A (ko) | 2010-01-19 | 2012-11-01 | 아스트라제네카 아베 | 피라진 유도체 |
EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
MX2012013081A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
EP2569289A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
CN102947272A (zh) | 2010-05-12 | 2013-02-27 | 沃泰克斯药物股份有限公司 | 用作atr激酶抑制剂的2-氨基吡啶衍生物 |
EP2569286B1 (en) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
US8623869B2 (en) | 2010-06-23 | 2014-01-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
MX2013011450A (es) | 2011-04-05 | 2014-02-03 | Vertex Pharma | Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
JP6050335B2 (ja) | 2011-05-23 | 2016-12-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | チアゾール誘導体 |
ES2699256T3 (es) | 2011-05-23 | 2019-02-08 | Merck Patent Gmbh | Piridina y derivados de pirazina |
JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
DE102011112978A1 (de) | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | Benzonitrilderivate |
MX2014003796A (es) | 2011-09-30 | 2015-01-16 | Vertex Pharma | Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
CA2850566C (en) | 2011-09-30 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative |
IN2014CN02501A (pt) | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776420A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
DE102011119127A1 (de) | 2011-11-22 | 2013-05-23 | Merck Patent Gmbh | 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate |
SI2812337T1 (sl) | 2012-02-09 | 2017-01-31 | Merck Patent Gmbh | Furo (3,2-b) in tieno (3,2-b) piridinski derivati kot zaviralci tbk1 in ikk |
JP2015515478A (ja) | 2012-04-05 | 2015-05-28 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物及びそれらの併用療法 |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
PL3808749T3 (pl) | 2012-12-07 | 2023-07-10 | Vertex Pharmaceuticals Incorporated | Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych |
WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
JP6543252B2 (ja) | 2013-12-06 | 2019-07-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ATRキナーゼ阻害剤として有用な2−アミノ−6−フルオロ−N−[5−フルオロ−ピリジン−3−イル]ピラゾロ[1,5−a]ピリミジン−3−カルボキサミド化合物、その調製、その異なる固体形態および放射性標識された誘導体 |
CA2945263A1 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
MX2016015874A (es) | 2014-06-05 | 2017-03-27 | Vertex Pharma | Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo. |
PT3157566T (pt) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
US10472347B2 (en) | 2014-11-18 | 2019-11-12 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with A2A antagonist properties |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA26473A1 (fr) * | 1997-03-01 | 2004-12-20 | Glaxo Group Ltd | Composes pharmacologiquement actifs. |
WO2001060806A2 (en) * | 2000-02-16 | 2001-08-23 | Neurogen Corporation | Substituted arylpyrazines |
EP1263745B1 (de) * | 2000-03-07 | 2004-05-19 | Aventis Pharma Deutschland GmbH | Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one und ihre verwendung zur hemmung der hormonsensitiven lipase |
AR029489A1 (es) * | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
CN1329382C (zh) * | 2001-05-11 | 2007-08-01 | 比奥维特罗姆股份公司 | 治疗肥胖、ⅱ型糖尿病和cns-疾病的芳基磺酰胺化合物 |
SE0102439D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
JP2003081937A (ja) * | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
SE0203752D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
-
2002
- 2002-12-17 SE SE0203754A patent/SE0203754D0/xx unknown
-
2003
- 2003-12-15 KR KR1020057011137A patent/KR101110457B1/ko not_active IP Right Cessation
- 2003-12-15 ES ES03781204T patent/ES2337682T3/es not_active Expired - Lifetime
- 2003-12-15 EP EP03781204A patent/EP1575938B1/en not_active Expired - Lifetime
- 2003-12-15 CA CA2508042A patent/CA2508042C/en not_active Expired - Fee Related
- 2003-12-15 MX MXPA05006243A patent/MXPA05006243A/es active IP Right Grant
- 2003-12-15 AU AU2003287135A patent/AU2003287135B2/en not_active Ceased
- 2003-12-15 BR BR0317294-5A patent/BR0317294A/pt not_active IP Right Cessation
- 2003-12-15 JP JP2004560223A patent/JP4674088B2/ja not_active Expired - Fee Related
- 2003-12-15 WO PCT/SE2003/001955 patent/WO2004055005A1/en active Application Filing
- 2003-12-15 AT AT03781204T patent/ATE454382T1/de not_active IP Right Cessation
- 2003-12-15 US US10/539,543 patent/US7585853B2/en not_active Expired - Fee Related
- 2003-12-15 CN CNB2003801066631A patent/CN100351250C/zh not_active Expired - Fee Related
- 2003-12-15 EP EP09180635A patent/EP2161265A3/en not_active Withdrawn
- 2003-12-15 NZ NZ540449A patent/NZ540449A/en not_active IP Right Cessation
- 2003-12-15 DE DE60330910T patent/DE60330910D1/de not_active Expired - Lifetime
-
2005
- 2005-06-06 IL IL169016A patent/IL169016A/en not_active IP Right Cessation
- 2005-07-15 NO NO20053460A patent/NO331495B1/no not_active IP Right Cessation
-
2006
- 2006-01-16 ZA ZA200504617A patent/ZA200504617B/en unknown
- 2006-01-19 HK HK06100896.9A patent/HK1080856A1/xx not_active IP Right Cessation
-
2009
- 2009-08-21 US US12/545,213 patent/US20100075989A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20050084363A (ko) | 2005-08-26 |
MXPA05006243A (es) | 2005-08-19 |
ATE454382T1 (de) | 2010-01-15 |
JP2006513180A (ja) | 2006-04-20 |
NZ540449A (en) | 2008-02-29 |
KR101110457B1 (ko) | 2012-02-17 |
ZA200504617B (en) | 2006-03-29 |
AU2003287135B2 (en) | 2007-01-25 |
CN100351250C (zh) | 2007-11-28 |
WO2004055005A1 (en) | 2004-07-01 |
EP2161265A3 (en) | 2010-06-02 |
WO2004055005A8 (en) | 2005-06-30 |
CN1729185A (zh) | 2006-02-01 |
SE0203754D0 (sv) | 2002-12-17 |
DE60330910D1 (de) | 2010-02-25 |
NO20053460L (no) | 2005-08-12 |
NO331495B1 (no) | 2012-01-16 |
EP1575938A1 (en) | 2005-09-21 |
EP2161265A2 (en) | 2010-03-10 |
AU2003287135A1 (en) | 2004-07-09 |
HK1080856A1 (en) | 2006-05-04 |
ES2337682T3 (es) | 2010-04-28 |
US7585853B2 (en) | 2009-09-08 |
CA2508042C (en) | 2012-01-10 |
IL169016A (en) | 2013-08-29 |
JP4674088B2 (ja) | 2011-04-20 |
CA2508042A1 (en) | 2004-07-01 |
EP1575938B1 (en) | 2010-01-06 |
US20060116362A1 (en) | 2006-06-01 |
US20100075989A1 (en) | 2010-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0317294A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários | |
HUP0400636A2 (hu) | Azetidinszármazékokat tartalmazó gyógyszerkészítmények, új azetidinszármazékok és előállításuk | |
HUP0401307A2 (hu) | 5-HT6 hatással rendelkező új indolszármazékok, eljárás az előállításukra, és ezeket tartalmazó gyógyszerkészítmények | |
SE0104334D0 (sv) | Therapeutic agents | |
EP1566379A4 (en) | QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME | |
MXPA04007414A (es) | Indoles sustituidos como agonistas alfa-1. | |
UY27384A1 (es) | Analogos de prostaglandina | |
MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
NO20015172L (no) | 1-metyl-erytromycin-derivater | |
SE9901573D0 (sv) | New compounds | |
NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
AU8799201A (en) | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | |
HUP0301458A2 (hu) | Benzoxazinonszármazékok, eljárás előállításukra és a vegyületek felhasználása | |
CY1107753T1 (el) | 2,5-δισυποκατεστημενο 3-μερκαπτοπεντανοϊκο οξυ | |
SE0102440D0 (sv) | New compound | |
HUP0100024A2 (hu) | Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények | |
MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
HUP0002929A2 (hu) | Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények | |
ITMI20042475A1 (it) | Uso di derivati tiazolidinonici come agenti terapeutici | |
NO20044531L (no) | Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom | |
SE9901572D0 (sv) | New compounds | |
SE9900190D0 (sv) | New compounds | |
NZ543068A (en) | Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2284 DE 14/10/2014. |